24-Apr-2026
No headlines found.
Business Wire (Thu, 5-Mar 7:30 AM ET)
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Silence Therapeutics PLC - American Depository Share trades on the NASDAQ stock market under the symbol SLN.
As of April 24, 2026, SLN stock price declined to $7.70 with 714,667 million shares trading.
SLN has a beta of 2.02, meaning it tends to be more sensitive to market movements. SLN has a correlation of 0.09 to the broad based SPY ETF.
SLN has a market cap of $363.55 million. This is considered a Small Cap stock.
Last quarter Silence Therapeutics PLC - American Depository Share reported $34,000 in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-7 million and exceeded earnings estimates by $.16.
In the last 3 years, SLN traded as high as $27.72 and as low as $1.97.
The top ETF exchange traded funds that SLN belongs to (by Net Assets): IBB, GWX, IBBQ, BIB.
SLN has outperformed the market in the last year with a price return of +119.4% while the SPY ETF gained +31.9%. SLN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +35.8% and +34.4%, respectively, while the SPY returned +3.8% and +5.1%, respectively.
SLN support price is $7.39 and resistance is $8.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLN shares will trade within this expected range on the day.
